A Phase 4 interventional study of Platelet rich-plasma - PRP - intraosseous and intra-articular admnistration in Knee Osteoarthritis, sponsored by Universidade do Porto. Not yet recruiting at 2 sites in Portugal. Open to participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2024-08-06.
Sponsored by Universidade do Porto · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Osteoarthritis, Knee with a site in Portugal — 3 open to participants now, 3 under way, none of them phase 3. Osteoarthritis, Knee · Portugal.
Among the 12 studies in Osteoarthritis, Knee with a site in Portugal, this one is the 8th largest by planned enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2025, is the only one in phase 4, and was the 10th registered.
3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.
Browse Osteoarthritis, Knee studies →3 of the 12 studies in Osteoarthritis, Knee with a site in Portugal are open now. Recruiting first, the newest first:
Centro Hospitalar Universitario do Algarve · Sites in Portugal
Ages 18+
Associação para o Desenvolvimento do Centro Académico de Investigação e Formação Biomédica do Algarv · Sites in Portugal
Ages 50+
A study can be open while its sites in Portugal have not opened yet or have stopped. Only those recruiting at a site in Portugal →
Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.
This study: 45 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 68 across 2,719 interventional studies indexed under Osteoarthritis, Knee.
Median enrollment 88 across the 11 interventional studies, 60 across the 1 observational. Of the 7 that completed or were terminated, 2 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 12 have an industry lead sponsor. The 10 most frequent:
Universidade do Porto is the lead sponsor of 174 studies on the registry; 53 are open to participants now.
Universidade do Porto has 1 study filed under Osteoarthritis, Knee — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Osteoarthritis, Knee with a site in Portugal, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a prospective cohort clinical study. Due to logistic constraints at the sites of implementation, a randomized allocation will not be feasible (private clinic). Patients will be selected with the aim of matching for important confounders (sex and age) the grade of knee OA will be restricted to advance stages.
A prospective cohort clinical study. The matched sample will be divided into two groups. Group 1 will receive two intraosseous injections of PRP and another intra-articular injection of PRP on the same day.
Group 2 will only receive two intra-articular injections of PRP, separated by one week. One week before the PRP injection, both groups will receive an intra-articular injection of 20 mg triamcinolone hexacetonide.
The PRP is obtained from an autologous blood sample. PRP production consists of a 54 mL (PRP intra-articular) and 80 mL (PRP intraosseous) sample of venous blood from the cubital vein of the patient's upper limb, using 6 x 9 ml tubes, containing a 3.2% sodium citrate solution. The tubes will be centrifuged at 2400 rpm for 12 minutes at room temperature. It is obtained a suspended concentration of PRP that is carefully extracted using a pipette to avoid aspiration of leukocytes from the buffy coat (leukocyte-poor PRP [LP-PRP]). For group 1, it will be injected 4 mL intraosseous, and 8 mL intra-articular. Group 2 will be injected 8 ml of PRP twice (one each week). A total of 8 ml of PRP will be injected into the knee.
A hemogram will be used to analyze the blood sample and the PRP to evaluate their characteristics (concentration of red blood cells, concentration of white blood cells, concentration of platelets, and mean platelet volume); with this analysis, it will be also calculated the platelet concentration growth factor (between baseline blood sample and PRP). Besides concentration, it will also be calculated the total volume of platelets injected into the knee.
All procedures will be carried out in a laminar flow chamber (0.34 m/s) to avoid contamination. Following preparation, the PRP will be injected with the minimum time elapsed since its preparation (maximum 30 minutes).
The PRP is injected after the skin is prepared and draped. If needed, synovial fluid aspiration will be done before injections. With the patient lying in a supine position on the examination table, with the knees fully extended, the PRP intra-articular injection is performed in a sterile manner via a superolateral patellar approach under ultrasound guidance (Logiq E R8, GE Healthcare).
Regarding intraosseous injections, the location and exploration of the joint line, tibial plateau, and femoral condyle will be done with ultrasound. Following the identification of the articular line through ultrasound examination, the two insertion points for the intraosseous infiltrations in the knee are marked: 2 cm below the tibiofemoral joint line for the tibial plateau and 2 cm above the tibiofemoral joint line for the femoral condyle. The procedure is done for the affected knee compartment (medial or lateral).
To ensure effective and safe analgesia during the intraosseous infiltration procedure, a solution of 1% lidocaine (10 mg/mL). In summary, a 10 mL syringe will be filled with the previously mentioned specified solution and then injected at the marked points-the tibial plateau and femoral condyle. Approximately 4-5 mL will be injected along the path until contact is made with the periosteum, where the trocar will be inserted. An additional 4-5 mL will be injected after the insertion of the trocar. A 10-20 minute time interval will be observed before proceeding with the intraosseous infiltrations. The tibial plateau and femoral condyle will be targeted, and a 15-G trocar-biopsy needle system (1.8 mm diameter, 90 mm length, Arrow OnControl Aspiration needle set, Teleflex Medical Europe Ltd., Dublin, Ireland) will be placed on the tibial and condyle entry mark points. Subsequently, the trocar will be attached to a power driver (Arrow OnControl Powered Bone Access System, Teleflex Medical Europe Ltd., Dublin, Ireland) encased in a sterile plastic sleeve. The trocar will be advanced with precision while its placement is verified using ultrasound imaging. It will be positioned 2 cm below the articular line at a 45-degree angle in the tibial plateau, and 2 cm above the articular line at a 30-degree angle, penetrating 1.5-2 cm into the bone. Accurate depth measurement is made with laser marks on the trocar, spaced 1 cm apart. Once the correct position is confirmed, the power driver will be detached, and the needle core removed. Afterward, 6 mL of activated PRP will be injected through the trocar. Following the injection, the needle core will be reinserted and reattached to the power driver, and the trocar will be withdrawn. Intraosseous infiltration will be consistently performed at the same site in all procedures, as PRP is expected to distribute uniformly across the subchondral area regardless of tissue lesions.
After injection, patients are allowed to mobilize the knee joint, walk as desired and are instructed to apply ice over the injected area for the next 24-48 hours. Patients will be requested to avoid vigorous activity for a minimum of 10 days and to avoid taking NSAIDs for 7 days after injection. Consumption of acetaminophen (max 3 gm/day) will be allowed in the management of pain during the post-intervention period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Two intraosseous injections of PRP and another intra-articular injection of PRP on the same day.
Combination Product: Platelet rich-plasma - PRP - intraosseous and intra-articular admnistration
Patients submited to two intra-articular injections of PRP, separated by one week.
Combination Product: Platelet rich-plasma - PRP - intraosseous and intra-articular admnistration
Group 1 will receive two intraosseous injections of PRP and a subsequent/synchronous intra-articular injection of PRP on the same day. Group 2 will only receive two intra-articular injections of PRP, separated by one week.
PROM - Knee related Qol
Knee injury and Osteoarthritis Outcome Score (KOOS) - absolute value from the score (units). Min-Max (0-100) higher scores indicate better outcomes and a higher quality of life related to the knee
Time frame: baseline, and at follow-up of 3 months, 6 months and 12 months
PROM - PAIN
Visual analogic Score - PAIN (VAS) -absolute value from the score (units). Min-Max (0-10) higher scores indicate worse outcomes
Time frame: baseline, and at follow-up of 3 months, 6 months and 12 months
bone marrow edema -MRI
first scored dichotomous (yes/no)
Time frame: 1 month prior to the injection; 1 month to one year after intervention
bone marrow edema -MRI
BME will be classified using the criteria defined in the Whole-Organ Magnetic Resonance Imaging Score (WORMS). Range 0-3 Higher scores mean more medular edema.
Time frame: 1 month prior to the injection; 1 month to one year after intervention
Plan to share: No — This experimental study is safe for patients and will be carried out according to the principles of the Declaration of Helsinki and the European Union General Data Protection Regulation (GDPR). All data processing will be anonymous.
No publications or documents are linked to this record.
Start is estimated for Jan 2025; primary completion for Jul 2026, 18 months later.
Of 88 non-industry phase 4 interventional studies under Osteoarthritis, Knee, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 32. This study's planned 18 months is close to that.
Counting every sponsor, half of 97 studies reached it within 19 months; a quarter within 10 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.